February 18, 2003

ZIVENA TO BEGIN PHASE II CLINICAL TRIALS TO TREAT LUNG CANCER

Columbus, Ohio--Zivena, Inc., an emerging specialty pharmaceutical company focused on oncology, announced today that it has determined, in a Phase I trial, the treatment dose of its lead product, Resmycin^TM (doxorubicin HCl inhalation solution), and has extended the trial into patients with lung metastases from soft tissue sarcoma.

"We're pleased that Zivena has chosen to proceed with trials in soft tissue sarcoma," said Dr. John Murren of Yale University Medical Center, one of the major centers in the trial. "At Yale we have seen tumor response with Resmycin in soft tissue sarcoma patients during the Phase I trial, even in a patient who previously received doxorubicin by the intravenous route," he said.

"Most impressively, we believe that we are able to deliver higher concentrations of the chemotherapy drug to the lung than those achieved with standard doses given by the traditional intravenous route, but without many of the toxicities, like bone marrow suppression and hair loss," Murren said.

"Zivena has submitted a Phase II combination trial for review by several institutions for patients who have advanced non-small cell lung cancer," said Zivena President and CEO Dennis Cearlock. "That trial is designed to test Resmycin's effectiveness in first-line treatment with a current standard intravenous therapy combining the benefits of local and systemic treatment," he said. Zivena specializes in developing inhaled oncology drugs to treat lung cancer and cancer that has metastasized to the lungs.

Zivena is currently attempting to secure a series A round of financing and intends to use the proceeds to further its research program.

About Zivena

Zivena is an emerging specialty pharmaceutical company focused on developing inhaled oncology products. The company intends to develop a suite of proprietary drugs for treating primary and metastatic lung tumors.

The company has been issued method patents covering the use of several classes of chemotherapy drugs to treat cancer by inhalation. Drugs covered by these patents represent a source of proprietary products with different mechanisms of action and proven efficacy in treating cancer. The company also has a proprietary delivery system designed to eliminate the emission of fugitive aerosols.

Zivena, formed in December 2002, is commercializing the oncology intellectual property that was previously in the BattellePharma portfolio. For more information contact Katy Delaney at (614) 424-5544 or by email at delaneyk@battelle.org or Dave Westaway at (614) 340-2370 or by e-mail at westaway@battellepharma.com.

Note: This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below. Zivena conducts research in the biotechnology/pharmaceutical field where movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. Furthermore, our research, testing, pricing, marketing, and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. In addition, future sales of our products a re affected by reimbursement policies imposed by third party payors, including governments, private insurance plans, and managed care providers. These government regulations and reimbursement policies may affect the development, usage, and pricing of our products. In addition, while we have obtained patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated, or circumvented by our competitors. Because forward-looking statements involve risks and uncertainties, actual results may differ materially from current results expected by Zivena. Zivena is providing this information as of January 23, 2003, and expressly disclaims any duty to update information